Gonorrhea: Symptoms, Infection Control & Red Flags

Neisseria gonorrhoeae is a Gram-negative diplococcus that invades mucosal columnar epithelium. Infection triggers neutrophilic inflammation, mucopurulent discharge and tissue oedema; yet a substantial share of endocervical and extragenital infections produce minimal symptoms, particularly in cisgender women and in pharyngeal carriage. Surface antigens undergo antigenic variation, which contributes to immune evasion and helps explain repeat infections even after antimicrobial cure.

Bacterial tropism for the reproductive and gastrointestinal mucosa underpins both local syndromes and bacteraemic dissemination along pharyngeal or genital portals. Antimicrobial pressure has sequentially eroded penicillin, tetracycline and fluoroquinolone reliability, anchoring contemporary guidelines on injectable extended-spectrum cephalosporins and closely monitored alternatives.

Urethritis in patients with a penis classically brings burning dysuria and mucopurulent discharge within days of exposure; epididymal pain suggests ascending infection. Cervicitis may present only with vaginal discharge, spotting or deep dyspareunia—clinicians should maintain a low threshold for NAAT when risk factors cluster.

Rectal infection can be asymptomatic or mimic proctitis with urgency, bleeding or tenesmus. Pharyngeal carriage is usually silent but supports onward transmission. Neonatal conjunctivitis and juvenile gynaecological emergencies are rare but high-stakes presentations requiring specialist pathways.

Infection spreads through condomless vaginal, anal or oral sex with an infected partner; perinatal transmission during birth causes ophthalmia neonatorum. Highest incidence tracks young adulthood, prior STI, multiple partners, commercial sex networks and men who have sex with men where extragenital reservoirs are common.

Mucosal inflammation from gonorrhea or concurrent ulcerative STI facilitates HIV acquisition and onward transmission—offer opt-out HIV testing when diagnosing any bacterial STI. Structural inequities, homelessness and substance-use contexts often correlate with sporadic care; document nonjudgmental history-taking to avoid missing extragenital testing indications.

NAAT is the front-line assay for urogenital, rectal and pharyngeal specimens in service-ready laboratories; serum-based tests do not replace site-specific sampling. Urine NAAT is acceptable for asymptomatic men and for clinician- or self-collected vaginal protocols where validated, but it must be supplemented by rectal and pharyngeal swabs when exposure history or local epidemiology warrants.

Microscopy of Gram-stained urethral smear retains high specificity in symptomatic urethritis but is insensitive at endocervix, rectum or pharynx and should not reassure clinicians when clinical suspicion is strong and NAAT is pending. Culture with susceptibility reporting remains essential in treatment failure, pregnancy requiring legal documentation or suspected resistance clusters—coordinate with microbiology before discarding charcoal swabs.

Bedside specimen discipline

Label every swab with anatomical site, time and initials; teach patients about self-collection kits to reduce default. Follow aseptic technique per your specimen collection protocol, transport within laboratory windows and flag medicolegal samples chain-of-custody when sexual violence is disclosed.

• Chlamydia / Mycoplasma genitalium urethritis—overlapping discharge; rely on multiplex NAAT panels.
• Urinary tract infection—pyuria without mucopurulence; absence of sexual risk reduces STI probability but does not exclude it in MSM or pregnant patients.
• Genital herpes first episode—vesicles and lymphadenopathy outweigh discharge; virus-specific testing when in doubt.
• PID mimic—appendicitis, ovarian torsion or endometritis; imaging and surgical review when focal signs dominate.

CDC’s 2021 STI Treatment Guidelines position ceftriaxone as the cornerstone for uncomplicated gonorrhea: for example, 500 mg intramuscularly once in adults weighing <150 kg for urogenital, cervical or rectal infection, with dose escalation to 1 g when body mass is higher; treat pharyngeal infection with the 500 mg (or 1 g if heavy) regimen and discuss test-of-cure timelines because eradication can lag. Always cross-check the live guideline tables—regimens evolve with susceptibility data.

Add doxycycline 100 mg orally twice daily for seven days when Chlamydia trachomatis has not been excluded; in pregnancy use azithromycin per STI guideline rather than tetracyclines. Severe cephalosporin allergy management requires specialist input—oral ciprofloxacin or other agents may appear only when culture proves fluoroquinolone susceptibility in some jurisdictions; never improvise monotherapy when resistance surveillance is unknown.

Deliver intramuscular injection using large-volume gluteal or deltoid technique per local policy, observe post-anaphylaxis monitoring where mandated, and document lot number. Hospitalised DGI receives longer IV ceftriaxone courses with infectious diseases dosing; outpatient substitutions risk relapse.

↔On a small screen, swipe or scroll sideways to see the full table.

1. Trigger: symptoms, partner diagnosis or screening indication → collect risk-appropriate NAATs plus HIV/syphilis per pathway.
2. Door-to-needle: treat presumptively after consultation once severe sequelae risk exists (e.g., PID symptoms) while awaiting labs.
3. Chemoprophylaxis education: abstain through completion; review drug-drug interactions (warfarin, antacids with oral partners).
4. Partner index: trace back 60 days (or longer per local rule); offer EPT where lawful.
5. Follow-up NAAT: repeat at 3 months due to reinfection burden; sooner if symptoms recur.

Resistance stewardship means reporting treatment failures with cultures, avoiding leftover oral antibiotics from unrelated courses and maintaining pharmacy oversight on ceftriaxone stock in community clinics.

Pelvic inflammatory disease confers tubal scarring, ectopic pregnancy risk and chronic pain. Epididymo-orchitis threatens fertility. Perihepatitis (Fitz-Hugh–Curtis) may masquerade as biliary pain. DGI can produce septic arthritis needing surgical washout, endocarditis or meningitis in rare cases.

USPSTF recommends routine NAAT screening for gonorrhea in all sexually active women ≤24 years and older women at risk; HIV-prevention programmes often extend extragenital testing cadence for MSM. Condom negotiation, PrEP integration and vaccination research (e.g., meningococcal vaccines showing cross-protection signals) sit alongside behavioural counselling—document brief interventions without moralising.

Uncomplicated infection resolves within days of appropriate therapy, yet reinfection remains common when partners remain untreated. Chronic pain or infertility reflects delayed PID care more than a single adequately treated episode. DGI generally responds to prolonged cephalosporin therapy when joints are drained promptly.

Psychological safety & disclosure

Use neutral language about partners and practices; offer chaperones for intimate exams. Interpreter access must precede informed consent for minors or safeguarding triggers.

Medication teaching

Emphasise completing oral doxycycline despite symptom resolution; counsel photosensitivity, Esophageal injury prevention with upright dosing and sucrose-free options when vomiting.

Information governance

Sexual health records often carry sensitive flags—avoid inadvertent display on open ward rounds; use secure messaging for partner-notification outcomes.

• Vital signs and early-warning score after IM ceftriaxone or first IV dose.
• Pain score, joint range and weight-bearing ability in suspected DGI.
• Oral intake tolerance when co-prescribing doxycycline or azithromycin.
• Pregnancy status documented before issuing tetracyclines.
• Partner notification tasks assigned with named clinic contact.
• Culture transport logged when resistance testing requested.

• Hypotension, tachycardia, rigors or lactate elevation after STI diagnosis—activate sepsis bundle.
• Single hot swollen joint with fever—urgent aspiration, withhold antibiotics only briefly if crystals unconfirmed but do not delay antimicrobials when gonococcus is likely.
• Vision-threatening eye injection or neonate with chemosis—immediate ophthalmic referral.
• Suspected obstetric sepsis or refractory pelvic pain—senior OB-GYN review and imaging.

Pre-alert receiving teams with sexual history summary, recent antibiotic exposure and pregnancy status so IV access and combined specialty assessment proceed without repetition of intimate history.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of extragenital NAAT indications, cephalosporin-first therapy, disseminated gonococcal infection (DGI) recognition and partner-notification ethics—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.